Clinical trials: Psychomotor Impairment
Depressive Disorder, Major
A Study of GW856553X For the Treatment of Depression
GW856553 is a novel compound, currently in development for the treatment of Major Depressive Disorder (MDD), and other indications.
- Trial name
- NCT00569062
- Testing
- GW856553X
- Where
- 15 sites in Estonia, India and 1 more
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Skeletal Abnormalities, Psychomotor Retardation
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Mucolipidosis Disorder type I,II,III or IV from blood (plasma)
- Trial name
- BioML (NCT02298673)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Depressive Disorder, Major
Clinical Study to Test a New Drug to Treat Major Depression
In this randomized, double-blind, multi-centre, placebo controlled, exploratory, adaptive design study, the antidepressant and plasma cytokine lowering effects of the GW856553 will be investigated in adult subjects diagnosed with…
- Trial name
- PKI113009 (NCT00976560)
- Testing
- GW856553
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 128 people
- Sponsor
- GlaxoSmithKline
Memory Impairment, Alzheimer's Disease
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.
- Trial name
- NCT02051335
- Testing
- Roflumilast, Donepezil, Scopolamine
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca